Publication date: Dec 01, 2024
To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273. Approximately 17 000 participants from the phase 3 Coronavirus Efficacy trial who previously received 2 doses of 100 ug mRNA-1273 were evaluated for COVID-19 between September 2021 and April 2022 during uptake of a third booster dose of 50 ug of mRNA-1273. Cox models assessed booster relative efficacy of a third dose. Initial booster relative efficacy against Delta COVID-19 was 83% (95% confidence interval, 60-93) 14 days postdose and 83% (67-91) 60 days later. Initial booster efficacy against Omicron COVID-19 was 56% (44-65) at 14 days postdose and 4% (-27 to 28) 120 days later. For those aged ≥65 years, initial booster efficacy against Omicron COVID-19 was 86% (69-93) compared with 50% (36-61) for those
Open Access PDF
Concepts | Keywords |
---|---|
100g | booster dose |
April | COVID-19 vaccine |
Coronavirus | mRNA-1273 |
Models | SARS-CoV2 |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | Infectious Diseases |
drug | DRUGBANK | Etodolac |
disease | MESH | Allergy |
drug | DRUGBANK | Coenzyme M |